CD19 and neoplasm: Of note, averages of BCL6+/pSTAT6− and BCL6−/pSTAT6+ fractions surmount to ~46% of the tumor cells in primary PMBL cases leaving ~54% CD19+ BCL6−/pSTAT6− cells.